Enter each component's milligrams and the bacteriostatic water you added to get what one syringe draw carries of each peptide. The default is the formulation the compound page describes — 10 mg tesamorelin + 3 mg ipamorelin in one vial — and no dose has been established for the blend. The blend itself is covered in the Tesamorelin + Ipamorelin guide.
A Tesamorelin + Ipamorelin vial holding 10 mg Tesamorelin + 3 mg Ipamorelin (13 mg total), reconstituted with 2 mL of bacteriostatic water, gives 5.0 mg/mL of Tesamorelin and 1.5 mg/mL of Ipamorelin — 50 mcg and 15 mcg per unit respectively on a U-100 syringe. For a 2 mg Tesamorelin dose, draw the syringe to 40.0 units (0.40 mL). That draw also delivers 600 mcg of Ipamorelin. At that dose the vial provides about 5 doses.
Defaults: 10 mg + 3 mg (13 mg, 10:3) is the formulation on the Tesamorelin + Ipamorelin compound page; 2 mL was chosen for simple arithmetic; 2 mg of tesamorelin is the "Standard (FDA)" row of the tesamorelin calculator, used for arithmetic only — there is no approved dose for the blend.
| Peptide | Vial Amount | Concentration | Dose per Draw | Doses from Vial |
|---|---|---|---|---|
| Tesamorelin ★ | 10 mg | 5000.0 mcg/mL | 2.00 mg | 5 |
| Ipamorelin | 3 mg | 1500.0 mcg/mL | 600.0 mcg | 5 |
Tesamorelin + Ipamorelin is a two-peptide growth-hormone-secretagogue blend in one vial, sold for research use only. Tesamorelin is a stabilised GHRH analog — the active ingredient in the FDA-approved drug Egrifta — and ipamorelin is a selective ghrelin-receptor (GHS-R) agonist. The table sets out what the compound page states (page last updated September 2026, read 21 September 2026), and at what level of evidence.
| Question | What the compound page states | Evidence level |
|---|---|---|
| What is in the vial? | Most commonly 10 mg tesamorelin + 3 mg ipamorelin — 13 mg in total, a fixed 10:3 ratio | Most common formulation; composition varies by vendor |
| Is it FDA-approved? | Only tesamorelin, as its own product (Egrifta), for excess abdominal fat in HIV-associated lipodystrophy. Research-grade tesamorelin in blends is not approved; ipamorelin is not approved for any indication | Split — the blend is not approved |
| Trials of the blend? | No controlled clinical trial of the combination published as of August 2026 | None |
| A dose for the blend? | None — no trial has established a dose for the combination | None — declined |
| Route? | Not stated | — |
Both peptides dissolve in the same water, so one volume sets both concentrations at once. With the default 2 mL, the 10 mg of tesamorelin is 5 mg/mL (50 mcg per unit on a U-100 syringe) and the 3 mg of ipamorelin is 1.5 mg/mL (15 mcg per unit). Every draw carries the two in the vial's 10:3 proportion: choose the amount of one component and the other is decided for you. The calculator above lets you pick which component your amount refers to; the only way to change one without the other is a vial with a different composition.
Peptigrity does not recommend a dose, and no dose has been established for the blend. The table shows what a draw carries from a 10 mg + 3 mg vial with 2 mL (the page default), as arithmetic on the label's ratio. Two rows convert the tesamorelin figures the compound page states — the original-approval dose of 2 mg/day and the 1.4 mg of the current EGRIFTA SV reformulation — both for HIV-associated lipodystrophy under medical supervision, neither a dose for the blend.
| Draw (U-100) | Volume | Tesamorelin | Ipamorelin | Note |
|---|---|---|---|---|
| 10 units | 0.10 mL | 500 mcg | 150 mcg | Arithmetic |
| 20 units | 0.20 mL | 1 mg | 300 mcg | Arithmetic |
| 28 units | 0.28 mL | 1.4 mg | 420 mcg | The EGRIFTA SV tesamorelin figure (HIV lipodystrophy) |
| 40 units | 0.40 mL | 2 mg | 600 mcg | The original-approval tesamorelin figure (HIV lipodystrophy) |
| 100 units | 1.00 mL | 5 mg | 1.5 mg | One full 1 mL barrel |
Arithmetic: units × 50 mcg gives the tesamorelin, units × 15 mcg the ipamorelin. The vial's 10 mg of tesamorelin covers about 5 draws of 2 mg and about 7.1 draws of 1.4 mg; that count does not change with the water volume, only the units each draw takes.
Tesamorelin + Ipamorelin has 34 independent lab tests on file at Peptigrity, from 7 laboratories across 23 vendors, as shown on its compound and lab-test pages on 21 September 2026. That is below the Purity Index inclusion threshold, so no index value is published for the blend yet. Its components are tested far more often on their own: tesamorelin averages 99.4% HPLC purity across 543 tests and ipamorelin 99.7% across 436 (same date).
The arithmetic above trusts the label's 10:3 ratio; a certificate is what checks it. The blend-vial certificates the compound page lists carry other labelled compositions too — 8 mg + 2 mg, 13 mg + 3 mg, 16 mg + 4 mg and 5 mg + 5 mg among them — so enter the amounts printed on your own vial. Net content can also depart from the label component by component: one certificate labelled 8 mg + 2 mg measured 5.4 mg of tesamorelin (32.5% under) and 5.44 mg of ipamorelin (172% over), a real ratio near 1:1 rather than 4:1. Purity is not net content. See the Tesamorelin + Ipamorelin lab-test records.
No page on Peptigrity sets a diluent volume for this blend, and the compound page states no route, so the volume is a choice and this page names no injection method. The water decides both concentrations together: 1 mL in a 10 mg + 3 mg vial doubles both (100 mcg of tesamorelin and 30 mcg of ipamorelin per unit), halving every draw in units without changing the ratio. The technique is covered once, elsewhere, as general guidance rather than a finding about this blend: reconstituting peptides step by step and the bacteriostatic water guide.
The picture is split. Tesamorelin is FDA-approved as Egrifta for the reduction of excess abdominal fat in HIV-associated lipodystrophy — its only approved indication — but the research-grade tesamorelin sold in blends is not an approved product and is supplied for research use only. Ipamorelin is not approved for any indication: ipamorelin acetate remains in Category 2 of the FDA's bulk-drug-substances evaluation (the 503B outsourcing-facility route), was not among the twelve peptides removed from Category 2 in April 2026, and is not on the Category 1 list, as of August 2026. The blend is not an approved product. For tested athletes, both components are prohibited at all times by WADA under Section S2.2.4 (growth-hormone-releasing factors) of the Prohibited List.
Each component has its own page and calculator: tesamorelin (tesamorelin calculator) and ipamorelin (ipamorelin calculator). The CJC-1295 pairing is at the CJC-1295 + Ipamorelin calculator, and any other composition fits the general blend calculator. Prices: no Tesamorelin + Ipamorelin offers were being tracked when read on 21 September 2026, and Peptigrity does not publish a price per mg for blends — see Tesamorelin + Ipamorelin prices.
With 2 mL of water the vial is 5 mg/mL of tesamorelin (50 mcg per unit) and 1.5 mg/mL of ipamorelin (15 mcg per unit), so 2 mg of tesamorelin is 40 units (0.40 mL) on a U-100 syringe, and that same draw also delivers 600 mcg of ipamorelin. With 1 mL of water it is 20 units, still with 600 mcg of ipamorelin.
There isn't one. No trial has established a dose for the combination, the blend is not an approved product, and Peptigrity does not recommend a dose. The approved tesamorelin dose (2 mg/day at original approval; 1.4 mg for the current EGRIFTA SV reformulation) applies to an HIV-associated lipodystrophy population under medical supervision, not to a blend.
Yes, but the tesamorelin follows. In a 10 mg + 3 mg vial with 2 mL each unit carries 50 mcg of tesamorelin and 15 mcg of ipamorelin, so 300 mcg of ipamorelin is 20 units and brings 1 mg of tesamorelin with it. In a blend you set the dose of one component and the other follows the fixed ratio.
No. Only tesamorelin is FDA-approved, as its own product (Egrifta), for excess abdominal fat in HIV-associated lipodystrophy. Research-grade tesamorelin sold in blends is not an approved product, ipamorelin is not approved for any indication, and the blend is not approved.
Not necessarily. Composition varies by vendor: the blend-vial certificates on file include 8 mg + 2 mg, 13 mg + 3 mg, 16 mg + 4 mg and 5 mg + 5 mg vials, so enter the amounts printed on your vial. Net content can also differ from the label for each component separately, which changes the real ratio; only a certificate that reports per-component net content can show it.